Key points from article :
CohBar announced the selection of CB5138-3 as its lead candidate for advancement into Investigational New Drug-enabling activities.
Discovered more than 100 mitochondrial derived peptides and generated over 1,000 analogs.
CB5138-3 is a CB5138 Analog, with potential for treatment of Idiopathic Pulmonary Fibrosis (IPF) and other fibrotic diseases.
“Positive preclinical data support CB5138-3 as a potential antifibrotic and anti-inflammatory therapeutic for IPF,” - Steven Engle, CohBar’s Chief Executive Officer.
Demonstrated positive effects including reduction of fibrosis, inflammation and collagen deposition.
Enhanced effects in combination with the standard of care nintedanib.
IND-enabling activities for CB5138-3 with the goal of initiating clinical studies in 2022.
CB4211 is in the Phase 1b stage for NASH and obesity.
Four preclinical programmes for fibrotic diseases, COVID-19 associated ARDS, cancer immunotherapy, CXCR4-related cancer and orphan diseases.
